Pharma Industry News

EU expands scope of Imbruvica to include untreated CLL patients

Treatment naïve patients lived longer without disease progression with the Imbruvica-based regimen than those given a chemotherapy-based oneOriginal Article

About the author

David Miller

a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.

[mwai_chat window="true" fullscreen="true"]